Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04913272
Other study ID # US-APR2020-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 24, 2021
Est. completion date December 2023

Study information

Verified date October 2022
Source Kibow Pharma
Contact Mukesh Kumar, PhD
Phone 2407504893
Email mkumar@fdamap.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this Phase 2 study is to evaluate the safety and efficacy of the live biotherapeutic product, KT-301 (formerly US-APR2020), in the management of patients with CKD Stage IV.


Description:

Kidney diseases are a global public health problem that affects over 200 million people worldwide. It is estimated that about 30 million adults in the United States have Chronic Kidney Disease (CKD) and most are undiagnosed. In addition, CKD represents the ninth leading cause of death in the United States. Kidney diseases also represent great socio-economical cost worldwide. In the United States, treating Medicare beneficiaries with CKD costed over $79 billion, and treating people with End Stage Kidney Disease (ESKD) costed an additional $35 billion in 2016. To date, there is no cure for CKD. The most important CKD risk factors in adults include diabetes and high blood pressure. Other risk factors include heart disease, obesity, a family history of CKD, past damage to the kidneys, and old age. Having CKD increases the chances of also having heart disease and stroke. CKD is a condition characterized by a gradual loss of kidney function over time. Depending on the kidney function measured with glomerular filtration rate (GFR) CKD can be classified into several stages (I, II, III, IV and V). CKD Stage V, also known as End Stage Kidney Disease (ESKD), is a very advanced stage of kidney disease where the kidneys have lost nearly all ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live. Treatment may slow the decline in kidney function and failure. However, not everyone with CKD develops ESKD, and in some cases ESKD develops even with treatment. CKD is accompanied by altered pathogenic gut bacteria, inflammation, and accumulation of uremic toxins in the blood. These blood uremic toxins can diffuse passively into the bowel. Scientific research has shown that probiotic bacteria could metabolize various uremic toxins such as urea, uric acid, and creatinine. In addition, by supplementing the gut microbiome with probiotic bacteria, it is possible to metabolize the nitrogenous waste products and other toxins which diffuse into the gut, and thus lower levels of inflammation and blood uremic toxins. KT-301 (formerly US-APR2020) is a live biotherapeutic (LBT) intended to restore the gut microbiome to improve the removal of uremic toxins in the bowel in CKD patients. The aim of this Phase 2 study is to evaluate the safety and efficacy of the KT-301 in the management of patients with CKD Stage IV.


Recruitment information / eligibility

Status Recruiting
Enrollment 630
Est. completion date December 2023
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Adults between the ages of 18-80 years - CKD Stage IV (eGFR = 15-29 mL/min) with declining kidney function for a period > 6 months - Serum Creatinine > 2.0 mg/dL - Adherence to low protein diet (LPD) of 0.6-0.8 g/kg/day based on subject response and on advisory Exclusion Criteria: - Those on probiotic supplements in the past 3 months - Pregnancy, breast feeding or females of child-bearing potential who are unwilling to use a reliable form of contraception. - Immunosuppressant medications therapy specific to immune mediated renal diseases - HIV/AIDs - Underweight (BMI = 18.5) - Subject with an infection that requires oral antibiotic administration at the time of randomization or close to that visit. - Those with gastrointestinal disease (irritable bowel syndrome or anal fissures or anal fistulas or perianal abscesses or perianal infections or diverticular diseases or colitis or colon polyps) at the time of screening and randomization, or within 6 months prior to the randomization visit (Visit 2) - Those with internal prosthesis including orthopedics, neurosurgery, heart valves, vascular stents ? 2 years post -surgery procedure. Those with Prosthesis > 2 years should not be excluded. - Those with biological/tissue grafts or prosthesis or implant - Those on anticoagulant medicines, including Vit K antagonists (e.g., warfarin, coumadin) or the new class of oral anti-coagulants approved by FDA in the last 10 years - Those on peritoneal dialysis - Those with acute kidney injury - Those with mental conditions or medically debilitating disease/disorder other than CKD, which, in the judgment of the investigator, would interfere with or serve as a contraindication to adherence to the study protocol or affect the ability to give informed consent or affect overall prognosis of the patient.

Study Design


Intervention

Drug:
US-APR2020
US-APR2020 capsules 45 billion CFUs of the LBT.
Placebo
Placebo

Locations

Country Name City State
United States Almeda Medical Clinic Houston Texas
United States South Carolina Clinical Research Orangeburg South Carolina
United States Kidney Michigan Saginaw Michigan
United States Jadedstone Clinical Research Silver Spring Maryland
United States Mendez Center for Clinical Research Woodbridge Virginia

Sponsors (1)

Lead Sponsor Collaborator
Kibow Pharma

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate incidences of Treatment-Emergent Adverse Events following KT-301 (formerly US-APR2020) administration in patients with Chronic Kidney disease (CKD) Stage IV as a measure of safety. Presence of adverse events in less than 10% of the study population, as a measure of safety six months
Primary Evaluate the change of eGFR as per NKF-USFDA guidelines following KT-301 (formerly US-APR2020) administration in patients with Chronic Kidney disease (CKD) Stage IV as a measure of clinical efficacy. Arresting the change of Estimated glomerular filtration rate (eGFR) as per National Kidney Foundation- US Food and Drug Administration (NKF-USFDA )guidelines in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo, as a measure of efficacy. six months
Secondary Evaluate changes in basic blood uremic metabolic markers Change in any of the basic blood uremic metabolic markers in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo:
Blood Urea Nitrogen (BUN)
Uric acid
Serum creatinine
Urea/creatinine ratio
Micro albumin urea
six months
Secondary Evaluate changes in complete blood count and hematology parameters Change in any of the complete blood count (CBC) and hematology parameters in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo:
Red blood cells
White blood cells
Platelets
Hemoglobin (Hgb)
Hematocrit (Hct) Ferritin
six months
Secondary Evaluate changes in C-Reactive Protein (CRP) levels Change in C-Reactive Protein (CRP) levels in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo six months
Secondary Evaluate change in quality of life (QOL)- SF36 QOL questionnaire six months
See also
  Status Clinical Trial Phase
Completed NCT05630729 - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management N/A
Completed NCT03293446 - AC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls N/A
Completed NCT04858854 - Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2 N/A
Completed NCT05624840 - Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
Recruiting NCT05489120 - Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD) N/A
Completed NCT04207203 - Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study N/A
Completed NCT05042206 - Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease Phase 1
Completed NCT05153174 - Study of Sulphoraphane in Chronic Kidney Disease Phase 1/Phase 2
Recruiting NCT03582982 - Flywheel Exercise for CKD N/A
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Not yet recruiting NCT03348839 - Medico-economic Impacts of NeLLY Service for Not on Dialysis Severe Chronic Kidney Disease N/A
Recruiting NCT04330807 - Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease N/A
Completed NCT05931978 - Effect of a CKD Dashboard on Patient Activation and Shared Decision Making N/A
Recruiting NCT05543928 - Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism Phase 3
Active, not recruiting NCT06037265 - PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System N/A
Completed NCT04617431 - Application of Wearable Devices to Build a Self-Management Model in Chronic Kidney Disease Patients N/A
Recruiting NCT04336033 - Validation and Evaluation of a Newly Developed Mobile Diet App N/A
Recruiting NCT05138419 - A Pragmatic Approach to CKD Patient Education N/A
Not yet recruiting NCT06394544 - Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment N/A
Recruiting NCT01410617 - The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass Phase 2/Phase 3